Pediatric Androgenetic Alopecia: An Updated Review

In this study, low-dose oral minoxidil was found to improve hair density in 80% of pediatric patients with androgenetic alopecia or telogen effluvium, with mild side effects primarily reported.

This study suggests that pediatric androgenetic alopecia is often associated with metabolic syndrome risk factors, highlighting the importance of early diagnosis for potential future health complications.

This review discusses treatment options for various types of alopecia in children and reports no new clinical results; it analyzes the existing literature on safety and efficacy.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This review found that oral spironolactone is an effective and well-tolerated treatment for androgenic alopecia in women, especially when used with topical minoxidil, with generally minimal side effects reported.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

This research letter reports that low-dose oral minoxidil improved hair density and length in children with loose anagen hair syndrome.

This study found that topical minoxidil 5% gel and spironolactone 1% gel were both effective treatments for androgenetic alopecia, with a combination of both providing the best clinical response and achieving 100% effectiveness among participants.

This study observed objective improvement in androgenetic alopecia in 5 out of 6 adolescent girls treated with 2.5 mg oral minoxidil and spironolactone, and reported no adverse effects.

This article reviews the classification, diagnosis, and management of hair disorders, emphasizing the role of trichoscopy and early diagnosis for effective treatment but reports no new clinical findings.

This pharmacovigilance study found an increased association of suicidality and psychological adverse events with finasteride use, especially among younger patients using it for alopecia.

This study reported that oral minoxidil improved hair density and had an acceptable safety profile in women with androgenetic alopecia.

This review discusses the use of topical and oral minoxidil for pediatric hair disorders, pointing out the lack of guidelines and the potential risks associated with systemic absorption, but reports no clinical results.

This review discusses recent genetic findings on hormonal signaling pathways in androgenetic alopecia, reporting no new study results but highlighting the need for further investigation.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.

This review examines the pharmacology, clinical efficacy, and adverse effects of oral finasteride for female pattern hair loss, and discusses potential new treatments like topical finasteride and dutasteride, but reports no new clinical results.

Low-dose oral minoxidil effectively treats female hair loss with good safety.

This review discusses female androgenetic alopecia, highlighting its diagnostic challenges and management strategies, but it reports no new results.

This study found that androgenetic alopecia is a significant yet under-recognized cause of hair loss in children and adolescents, often linked to family history and typically diagnosed by clinical examination.

This review discusses the role of androgen hormones in the pathophysiology of childhood androgenetic alopecia and reports no clinical results.

This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with male androgenetic alopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.

This abstract suggests that specific trichoscopic features like black dots, coiled hair, and trichoptilosis may help differentiate trichotillomania from patchy alopecia areata.

Changing hairstyles can help hair regrow in children with hair loss from tight braids or ponytails.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This review presents various trichoscopic findings for diagnosing alopecia areata but reports no new clinical results, emphasizing that no single marker is pathognomonic and multiple features should be considered together.

Taking 5 mg/day finasteride can cause side effects in women with hair loss, but these are usually mild and fade over time, making the treatment beneficial in the long run.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This case report describes a 5-year-old child in Brazil who developed generalized hypertrichosis after using topical minoxidil, suggesting caution when using it in children.

This article examines various types of childhood alopecia and highlights the importance of identifying chronic conditions or those linked to underlying medical issues, but reports no new results.

This case report details a 2-year-old boy who developed generalized hypertrichosis after using 5% minoxidil foam for alopecia areata, highlighting the importance of caution and proper administration instructions for young children.

Trichoscopy is a useful non-invasive method for diagnosing different hair loss conditions.

This review discusses the use of trichoscopy in diagnosing and managing pediatric hair and scalp disorders and reports no new experimental findings.

This study found that 5 mg/day oral finasteride was effective and safe for improving hair outcomes in normoandrogenic postmenopausal women with androgenetic alopecia over 18 months.

This paper discusses spironolactone as a potential off-label treatment for female pattern hair loss, noting its ability to halt hair loss progression and induce partial regrowth in a significant number of women but reports no new clinical results.

This study found that androgenetic alopecia is the leading cause of hair loss in adolescents and may indicate endocrine disorders, emphasizing the need for accurate diagnosis.

In this study, a 9-year-old girl with female pattern hair loss showed clinical improvement and hair regrowth after six months of daily oral spironolactone.

This study outlines the clinical features of androgenetic alopecia in Korean adolescents, finding milder symptoms compared to adults and a high occurrence of family history, with normal hormone levels.

This review discusses the importance of androgen production and metabolism in hyperandrogenism, the use of specific serum markers for diagnosis, and the need for improved assays for clinical testing, but reports no new results.

In this case series, researchers observed androgenetic alopecia in 20 prepubertal children with a strong genetic predisposition, despite the condition typically not occurring before puberty.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

This review discusses various pediatric hair loss conditions and treatments, highlighting the importance of a holistic approach and noting that no single treatment is universally effective.